FDA Regulation of Pharmaceuticals and Devices FDA Organizational
- Slides: 44
FDA Regulation of Pharmaceuticals and Devices
FDA Organizational Chart Department of Health and Human Services Center for Veterinary Medicine Center for Food Safety And Applied Nutrition Food and Drug Administration Office of the Commissioner National Center for Toxicological Research Center for Drug Evaluation And Research (CDER) Center for Biologics Evaluation and Research (CBER) Center for Devices and Radiological Health (CDRH)
CDRH Mission: Ensure medical devices are safe and effective via premarket and postmarket evaluation • guide manufacturers in product development • evaluate data submitted on device design, performance, and clinical use • authorize marketing of devices found safe and effective • ensure that claims are supported by valid scientific evidence • focus special emphasis on medical breakthrough devices (expedited review)
Total Product Life Cycle Coated Stents Brachytherapy
Total Product Life Cycle
FDA • FDA regulations found in Title 21, Code of Federal Regulations – 21 CFR • Regulate products • Coverage includes – but not limited to: – – – – Nonclinical studies Clinical studies Human Subject Protection Institutional Review Boards (IRBs) Manufacturing Labeling Post-market adverse event reporting
FDA • FDA regulations “speak” to: – Importers/exporters – Study sponsors – Nonclinical laboratory personnel – Clinical investigators – IRBs – Medical product users – hospitals, clinics, nursing homes, individual practitioners
Pharmaceuticals versus devices • Pharmaceuticals (drugs and biologics) are covered by different FDA regulations from those covering devices, though some regulations are shared • Many differences result from differences among the products themselves
Nature of product Pharmaceuticals (drugs & biologics) • Molecular entities • Limited shelf life • Long market life • Potential for interactions with other drugs • Wrong drug/dose issues Devices • Complex components • Many = durable equipment • Short product cycles – “tweaking” of design • Device malfunctions • User errors
Nature of firms Pharmaceuticals • Large, often multinational firms • Extensive clinical trial experience Devices • Entrepreneurial firms common • Device “developer” often involved • Many have minimal clinical trial experience • Sponsor-investigators common
Studies Pharmaceuticals • Nonclinical – toxicology • Clinical Devices • Nonclinical – biocompatibility – nonclinical studies may suffice • Clinical – subject populations commonly 1000 s – subject populations usually 100 s – phases – pilot study possible + pivotal – routinely blinded – blinding less common – placebo = common control – “controls” vary – CI training often critical (Human Factor concerns)
Regulations Pharmaceuticals • 21 CFR Part 312 – IND • Part 314 – NDA • Part 600 – general biologics provisions • Part 601 – BLA Devices • 21 CFR Part 812 – IDE • Part 809 - IVDs • Part 814 – PMA • Part 807, Subpart E – 510(k)
Clinical Investigators -1 • Common responsibilities across products: – Personally conduct or supervise the study – Ensure site study team is properly trained – Follow FDA regulations regarding HSP, including obtaining and maintaining IRB approval and obtaining subject informed consent – Follow the approved investigational plan/protocol
Clinical Investigators -2 • CI responsibilities (cont. ): – Maintain adequate, complete, and accurate study records – Submit all required reports (e. g. , IND safety reports, study progress reports) – Maintain control of the investigational product
Sponsors -1 • Common responsibilities across products: – Obtain FDA approval, where necessary, before study initiation – Manufacture and label investigational products appropriately – Initiate, withhold, or discontinue clinical trials as required – Refrain from commercialization of investigational products – Maintain control of the investigational product
Sponsors -2 • Sponsor responsibilities (cont): – Select qualified investigators and disseminate appropriate information to them – Select qualified monitors and ensure the study is adequately monitored – Evaluate and report adverse experiences – Maintain adequate records – Submit progress and final reports
Regulatory distinctions -1 Pharmaceuticals • Adequate, well-controlled trials • CROs – 312. 52 = transfer of regulatory obligations • Form FDA 1572 • FDA agreement not usually required before enacting studies changes • AE reports during study may use Form 3500 A (Med Watch) – 312. 32(c)(B) Devices • Valid scientific evidence • CROs – regulations silent save for definition of monitor [812. 3(j)] • Investigator agreement [812. 43(c)] • Significant study changes require IDE supplement approval • AE reports during study not to go to Med. Watch (i. e. , not use MDR)
Regulatory distinctions -2 Pharmaceuticals Devices • Manufacturing – Part c. GMPs – Parts 210 & 820 (QSR) 211 + Part 606 for • MDRs for approved blood & blood devices are products mandatory – Part 803 • Med. Watch reports for approved pharmaceuticals are voluntary
Additional Device Distinctions -1 • Classes of Devices – risk-based determination – 21 CFR 860 – classification procedures – 21 CFR 862 through 892 – specific device classifications by product type
Additional Device Distinctions -2 • Cleared devices – 510(k) – 21 CFR 807, subpart E – Premarket Notification Procedures – “substantially equivalent” • Approved devices – 21 CFR Part 814 – PMA, PDP, HDE – Safety and effectiveness – PMA & PDP – Safety – HDE
Additional Device Distinctions -3 • Significant risk/non-significant risk studies • Exempt studies/in vitro diagnostics (IVDs) • Protocol changes and 5 -day notices
Significant Risk (SR) • Regulatory definition (21 CFR 812. 3(m)) – device that presents potential for serious risk to health, safety, or welfare of a subject, particularly if it • Is intended as an implant • Is purported or represented for use in supporting or sustaining life • Is for a use of substantial importance in diagnosing, curing, mitigating, or treating disease, or otherwise preventing impairment of human health
Non-Significant Risk (NSR) • • Decision based on use of device in study Sponsor makes initial assessment IRB makes determination FDA can disagree If NSR study, no IDE application to FDA Informed consent required Abbreviated requirements apply (21 CFR 812. 2(b)) • Considered to have an IDE
In Vitro Diagnostics (IVDs) • SR/NSR/exempt studies • Exempt if: • labeled according to 21 CFR 809. 10 • noninvasive sampling or no significant risk • does not introduce energy into a subject • not used as the diagnostic for determination of treatment
Significant Risk IVD Studies • If study involves invasive sampling that presents a significant risk • If results from use of an investigational IVD will determine treatment, could inaccurate results: - be life-threatening - result in permanent functional impairment - result in permanent structural damage - necessitate medical or surgical intervention to prevent impairment or damage
Clinical Investigators • Compliance inspection program covers study specific inspections and audits of CIs (physicians, veterinarians, others) conducting clinical trials on human and veterinary products • Usually preannounced • Inspection includes an interview with the clinical investigator and pertinent study staff + an in-depth study/data audit – to validate study findings and verify compliance with regulations
Most Common CI Deficiencies • • Failure to follow the investigational plan Protocol deviations Inadequate recordkeeping Inadequate accountability for the investigational product • Inadequate subject protection – including informed consent issues
Administrative/regulatory options • Untitled or Warning letter • Initiation of disqualification procedures • Sharing information with Office of Criminal Investigations (OCI) for pursuit of prosecution • Recommendation for rejection of site/study data
Institutional Review Boards (IRBs) • Board, committee, or other group formally designated by an institution to – review – approve the initiation of – conduct periodic review of research involving human subjects • Primary purpose of review = ensure protection of rights, safety, and welfare of the human subjects
Applicable regulations • 21 CFR Part 50 – Protection of Human Subjects – contains informed consent requirements • 21 CFR Part 56 – Institutional Review Boards – includes specifics of IRB’s makeup and duties
IRB Inspections • Compliance program provides for regularly scheduled inspections to verify compliance with regulations • Objective is protection of human subjects rather than data validation • Inspections – usually preannounced – consist of • interviews with responsible IRB staff • in-depth review of SOPs, files, and records • review of active studies to assess IRB operations
Most common IRB deficiencies • • Inadequate initial and/or continuing review Inadequate SOPs Inadequate membership rosters Inadequate meeting minutes Specific to devices – lack of or incorrect SR/NSR determination
Administrative/regulatory options • Untitled or Warning letter • Restriction of functions – prohibiting increase of subject population in on -going FDA-regulated studies – prohibiting review of new FDA-regulated studies • Initiation of disqualification procedures
Sponsors/CROs/Monitors • Compliance program – covers parties responsible for initiating and overseeing research and for submitting research results to FDA – lists sponsor responsibilities • Inspections – usually preannounced – consist of interviews and audits of study records – objective is to both evaluate compliance with regulations and validate data – commonly assigned for NDAs for new molecular entities (NMEs) and for PMAs
Most common S/M deficiencies • Inadequate monitoring • Failure to bring investigators into compliance • Inadequate accountability for the investigational product
Administrative/regulatory options • Untitled or Warning letter • Invocation of the Application Integrity Policy (AIP) • Refusal to accept site or study data • Denial of NDA/BLA/PMA • Sharing information with Office of Criminal Investigations (OCI) for pursuit of prosecution
Bioequivalence (BEQ) studies • Primarily support – Abbreviated drug applications (ANDA) for generic drugs – Applications for new form or formulation of marketed drugs • Compliance program – Provides for inspection of both clinical facilities and analytical laboratories involved with BEQ studies – Focuses on inspecting • • • New facilities Previously violative sites Suspicious data Non-conventional studies Studies pivotal to NDA decision-making
Resources - 1 • GCP website – http: //www. fda. gov/oc/gcp/ – Links include • pertinent regulations and guidance • FDA contacts • related sites with HSP/GCP information • Recent documents of interest relate to – – – Data monitoring committees Use of a centralized IRB AE reporting CI supervisory responsibilities Computerized systems in clinical trials
Resources - 2 • GCP queries e-mail account (about 1, 200 queries answered per year) – gcp. questions@fda. hhs. gov • Previous answers captured – http: //www. fda. gov/oc/gcp/redacted. Emails/default. htm • Listserve – via GCP website – notice of updates on FDA’s GCP/HSP activities • Site maintained by Good Clinical Practice Program (GCPP)
Acronyms -1 • • 510(k) – premarket notification AE – adverse event (or effect) AIP – Application Integrity Policy BEQ – bioequivalence BIMO – Bioresearch Monitoring BLA – biologics license application CBER – Center for Biologics Evaluation and Research • CDER – Center for Drug Evaluation and Research
Acronyms -2 • CDRH – Center for Devices and Radiological Health • CFR – Code of Federal Regulations • CI – clinical investigator • c. GMPs – current good manufacturing practices • CRO – contract research organization • DBM – Division of Bioresearch Monitoring • DSI – Division of Scientific Investigations • DQ – disqualification
Acronyms -3 • EIR – establishment inspection report • FDAMA – Food and Drug Administration Modernization Act (1997) • GCP – Good Clinical Practice • GCPP – Good Clinical Practice Program • HDE – humanitarian device exemption • HSP – human subject protection • HQ – headquarters • IDE – investigational device exemption • IND – investigational new drug
Acronyms -4 • • • IRB – institutional review board IVD – in vitro diagnostic MDR – medical device report NAI – no action indicated NDA – new drug application NME – new molecular entity NSR – non-significant risk OAI – official action indicated OHRP – Office of Human Research Protections
Acronyms -5 • OIVD – Office of In Vitro Diagnostic Device Evaluation and Safety • ORA – Office of Regulatory Affairs • PDP – product development protocol • PMA – premarket approval • QSR – quality system regulation • SOPs – standard operating procedures • SR – significant risk • VAI – voluntary action indicated
- Michael marcarelli
- Irbmakeup
- Sbir framework
- Nikita atal
- Contoso pharmaceuticals powerpoint
- Contoso pharmaceuticals
- Contoso pharmaceuticals
- Contoso pharmaceuticals
- Contoso pharmaceuticals powerpoint
- August bergqvist
- Ambalal sarabhai products list
- Vddi pharmaceuticals
- Samy shanmugam
- Newbury pharmaceuticals keskustelu
- Contoso pharmaceuticals
- Mccabes pharmacy discount code
- Lavet pharmaceuticals
- Vertex pharmaceuticals canada
- Phony pharmaceuticals speech
- Levolta pharmaceuticals
- Tamper resistant packaging definition
- Report pharma fraud
- Contoso ltd
- Vddi pharmaceuticals
- What are devices in literature
- Output and input devices of computer
- Fda v brown and williamson
- Thermoreceptor
- Section 4 gene regulation and mutation
- Table tennis regulations
- Thermoregulation
- How there is recyclability and self regulation in nature
- Regulation of glycolysis and gluconeogenesis
- 5 roles of an nco
- Regulation of recruitment and placement activities
- Chapter 12 section 4 gene regulation and mutations
- Table tennis rules and regulation
- Regulation and inspection of social care wales
- Government regulation and the legal environment of business
- Hines hill train crash
- Michigan department of licensing and regulatory affairs
- Licensing and regulation division
- Osha hazard and ghs training regulation cfr 1910
- Ground water management and regulation scheme
- Blood bank regulation under drugs and cosmetics act